TOKYO -- The coronavirus competition between the U.S. and China goes beyond developing a vaccine, as both countries aim to accelerate that process to unprecedented speeds in hopes of starting large-scale production by autumn.
U.S.-based Moderna lifted stock prices around the world Monday after it announced promising preliminary results, saying that eight subjects who received the company's vaccine candidate developed a similar or higher level of antibodies compared with recovered patients.
